AC
GILD icon

Avestar Capital’s Gilead Sciences GILD Stock Holding History

Avestar Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Buy
20,418
+1,191
+6% +$157K 0.14% 118
2026
Q1 		$2.68M Sell
19,227
-2,566
-12% -$359K 0.17% 100
2025
Q4 		$2.67M Buy
21,793
+2,639
+14% +$321K 0.17% 95
2025
Q3 		$2.13M Buy
19,154
+1,040
+6% +$118K 0.14% 121
2025
Q2 		$2.01M Buy
18,114
+4,296
+31% +$457K 0.14% 117
2025
Q1 		$1.55M Buy
13,818
+5,521
+67% +$570K 0.13% 131
2024
Q4 		$766K Buy
8,297
+1,362
+20% +$123K 0.07% 217
2024
Q3 		$581K Buy
6,935
+1,534
+28% +$117K 0.06% 239
2024
Q2 		$371K Buy
5,401
+568
+12% +$37.9K 0.04% 298
2024
Q1 		$354K Sell
4,833
-235
-5% -$18.1K 0.04% 303
2023
Q4 		$411K Buy
5,068
+1,274
+34% +$99.1K 0.05% 228
2023
Q3 		$284K Buy
3,794
+694
+22% +$53.4K 0.04% 265
2023
Q2 		$239K Buy
3,100
+596
+24% +$47.5K 0.04% 279
2023
Q1 		$208K Sell
2,504
-168
-6% -$13.9K 0.04% 287
2022
Q4 		$229K Buy
+2,672
New +$212K 0.04% 255
2021
Q2 		– Sell
-3,472
Closed -$224K – 455
2021
Q1 		$224K Buy
+3,472
New +$224K 0.05% 296
2020
Q3 		– Sell
-4,677
Closed -$360K – 235
2020
Q2 		$360K Sell
4,677
-7,476
-62% -$573K 0.16% 125
2020
Q1 		$909K Buy
12,153
+355
+3% +$24.5K 0.5% 49
2019
Q4 		$766K Sell
11,798
-325
-3% -$21.2K 0.43% 59
2019
Q3 		$768K Buy
12,123
+226
+2% +$14.8K 0.48% 47
2019
Q2 		$798K Buy
11,897
+5
+0% +$329 0.51% 45
2019
Q1 		$769K Buy
11,892
+26
+0.2% +$1.73K 0.51% 44
2018
Q4 		$739K Sell
11,866
-2
-0% -$140 0.5% 41
2018
Q3 		$913K Sell
11,868
-166
-1% -$12.5K 0.53% 34
2018
Q2 		$849K Sell
12,034
-9
-0.1% -$636 0.54% 36
2018
Q1 		$904K Buy
12,043
+51
+0.4% +$4.05K 0.59% 29
2017
Q4 		$855K Buy
+11,992
New +$911K 0.64% 19

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avestar Capital's GILD Position: Q2 2026 in Review

Avestar Capital increased its Gilead Sciences (GILD) stake by 6.2% in Q2 2026, buying an estimated $157K and bringing the position to 20,418 shares worth $2.58M. The position accounts for 0.14% of the portfolio, ranked #118.

Avestar Capital first reported a position in GILD in Q4 2017 and has held it in 27 quarters since. The position peaked at $2.68M in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Avestar Capital held 20,418 shares of Gilead Sciences worth $2.58M as of Q2 2026.
  • Avestar Capital bought 1,191 Gilead Sciences shares in Q2 2026, an estimated $157K.
  • Gilead Sciences made up 0.14% of Avestar Capital's portfolio in Q2 2026, its #118 holding.
  • Avestar Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 27 quarters since.
  • Avestar Capital's Gilead Sciences position peaked at $2.68M in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.